Palin takes aim at GOP presidential candidates

In the immediate aftermath of Monday's GOP presidential debate, former Alaska Gov. Sarah Palin (R) launched jabs at the entire Republican field, a move sure to ramp up speculation that the 2008 vice presidential candidate will make her own bid for the nomination. 

"They haven't tackled debt and deficit spending to the degree that they should, so they don't have a record to stand on," Palin said of the GOP candidates, all of whom serve or have served in public office, save businessman Herman Cain (R). 

Palin even went as far as to lend her voice to the charge leveled by Rep. Michele Bachmann (R-Minn.) during the debate against Texas Gov. Rick Perry (R): That he allowed a law to go though requiring HPV vaccinations for adolescent girls because of a $5,000 campaign donation and his relationship with his former chief of staff, who went on to lobby for a pharmaceutical company. 

"I knew there was something to it," Palin said of learning while she was Alaska's governor that her Texas counterpart had given the go-ahead to the vaccine. "Now we're finding that now, yea, something was up with that issue. It was an illustration or bit of evidence of some crony capitalism." 

Palin, who has crisscrossed the country making speeches and appearances in early voting states, decline once again to say whether she will run for president, but admitted she's enjoying driving the conversation. 

"I'm getting kind of a kick out of this," Palin said, claiming that the day after she brings up an issue, she notices the candidates adopt that issue in their stump speeches. "It's like come on candidates, it's about time you started talking about that." 

Palin was Sen. John McCain's (R-Ariz.) vice presidential candidate in 2008 and served about half of a term as Alaska's governor before resigning. Despite not having declared her candidacy, she polled third in a CNN-Opinion Research poll last week asking Americans who they would most likely support in a Republican primary.

More in Healthcare

Fiorina takes aim at drug companies, health insurers

Read more »